Sunday, August 31, 2025
Science
No Result
View All Result
  • Login
  • HOME
  • SCIENCE NEWS
  • CONTACT US
  • HOME
  • SCIENCE NEWS
  • CONTACT US
No Result
View All Result
Scienmag
No Result
View All Result
Home Science News Cancer

New directions in targeting the multifaceted BRAF in cancer

August 12, 2024
in Cancer
Reading Time: 4 mins read
0
Targeting the multifaceted BRAF in cancer: New directions
69
SHARES
628
VIEWS
Share on FacebookShare on Twitter
ADVERTISEMENT

“Here we discuss the diverse forms of BRAF alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.”

Targeting the multifaceted BRAF in cancer: New directions

Credit: 2024 Toye et al.

“Here we discuss the diverse forms of BRAF alterations found in human cancers and the strategies to inhibit them in patients harboring cancers of distinct origins.”

BUFFALO, NY- August 12, 2024 – A new research perspective was published in Oncotarget’s Volume 15 on July 16, 2024, entitled, “Targeting the multifaceted BRAF in cancer: New directions.”

In cancer patients, BRAF-targeting precision therapeutics are effective against Class I BRAF alterations (p.V600 hotspot mutations) in tumors such as melanoma, thyroid cancer, and colorectal cancer. However, numerous non-Class I BRAF inhibitors are also in development and have been explored in various cancers.

Researchers Eamon Toye, Alexander Chehrazi-Raffle, Justin Hwang, and Emmanuel S. Antonarakis from the Masonic Cancer Center, University of Minnesota-Twin Cities, Department of Medicine, University of Minnesota-Twin Cities, Perelman School of Medicine, University of Pennsylvania, and the City of Hope Comprehensive Cancer Center in Duarte, California, discuss the diverse forms of BRAF alterations found in human cancers and the strategies used to inhibit them in patients with cancers of various origins.

As part of their conclusion, the researchers highlighted that Class I BRAF inhibitors represent a landmark achievement in precision oncology, as demonstrated by the recent tissue-agnostic FDA approval of dabrafenib/trametinib for patients with metastatic BRAF p.V600E-mutant solid tumors. Additionally, the accelerated approval of tovorafenib for patients with relapsed/refractory BRAF-altered pediatric low-grade glioma underscores the therapeutic potential of this and other next-generation strategies targeting aberrant MAPK signaling.

Continue reading: DOI: https://doi.org/10.18632/oncotarget.28612 

Correspondence to: Emmanuel S. Antonarakis – anton401@umn.edu, and Justin Hwang – jhwang@umn.edu

Keywords: BRAF, MAPK, pan-cancer, precision oncology, genomics

Click here to sign up for free Altmetric alerts about this article.

About Oncotarget:

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).

To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:

  • X
  • Facebook
  • YouTube
  • Instagram
  • LinkedIn
  • Pinterest
  • Reddit
  • Spotify, and available wherever you listen to podcasts

Click here to subscribe to Oncotarget publication updates.

For media inquiries, please contact media@impactjournals.com.

Oncotarget Journal Office
6666 East Quaker Street., Suite 1
Orchard Park, NY 14127
Phone: 1-800-922-0957 (option 2)



Journal

Oncotarget

DOI

10.18632/oncotarget.28612

Method of Research

News article

Subject of Research

Not applicable

Article Title

Targeting the multifaceted BRAF in cancer: New directions

Article Publication Date

16-Jul-2024

COI Statement

A.C.R. reports personal fees from Exelixis, Inc. and Aveo, Inc. outside the submitted work. JH consults for Tempus and is a co-founder of EMRGNSE. E.S.A. reports grants and personal fees from Janssen, Sanofi, Bayer, Bristol Myers Squibb, Curium, MacroGenics, Merck, Pfizer, AstraZeneca, and Clovis; personal fees from Aadi Bioscience, Aikido Pharma, Astellas, Amgen, Blue Earth, Corcept Therapeutics, Exact Sciences, Hookipa Pharma, Invitae, Eli Lilly, Foundation Medicine, Menarini-Silicon Biosystems, Tango Therapeutics, Tempus and Z-alpha; grants from Novartis, Celgene, and Orion; and has a patent for an AR-V7 biomarker technology that has been licensed to Qiagen.

Share28Tweet17
Previous Post

AI poses no existential threat to humanity – new study finds

Next Post

“Long COVID” continues to evade diagnosis

Related Posts

blank
Cancer

Propranolol’s Potential Role in Cancer Treatment Explored

August 31, 2025
blank
Cancer

UBAP2L Deficiency Limits Colorectal Cancer Growth and Resistance

August 31, 2025
blank
Cancer

Juglone’s Autophagy Targets in Bladder Cancer Treatment

August 30, 2025
blank
Cancer

L-arginine vs. L-glutamine: A Mucositis Treatment Trial

August 30, 2025
blank
Cancer

Cancer Treatment’s Impact on Breast Cancer Survivors

August 30, 2025
blank
Cancer

Revisiting Conversion Therapy for Pancreatic Cancer Metastasis

August 30, 2025
Next Post

“Long COVID” continues to evade diagnosis

  • Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    Mothers who receive childcare support from maternal grandparents show more parental warmth, finds NTU Singapore study

    27542 shares
    Share 11014 Tweet 6884
  • University of Seville Breaks 120-Year-Old Mystery, Revises a Key Einstein Concept

    956 shares
    Share 382 Tweet 239
  • Bee body mass, pathogens and local climate influence heat tolerance

    642 shares
    Share 257 Tweet 161
  • Researchers record first-ever images and data of a shark experiencing a boat strike

    509 shares
    Share 204 Tweet 127
  • Warm seawater speeding up melting of ‘Doomsday Glacier,’ scientists warn

    313 shares
    Share 125 Tweet 78
Science

Embark on a thrilling journey of discovery with Scienmag.com—your ultimate source for cutting-edge breakthroughs. Immerse yourself in a world where curiosity knows no limits and tomorrow’s possibilities become today’s reality!

RECENT NEWS

  • Gamma Delta T Cells: New Frontiers in Transplantation
  • Advancing Biomedical Engineering: Crafting Industry-Ready Graduates
  • Postoperative Graft Mechanics in ACL Reconstruction Explored
  • Rewrite Demystifying programme theories of co-production in health and welfare: An interview study on new researchers’ systems perspectives as a headline for a science magazine post, using no more than 8 words

Categories

  • Agriculture
  • Anthropology
  • Archaeology
  • Athmospheric
  • Biology
  • Blog
  • Bussines
  • Cancer
  • Chemistry
  • Climate
  • Earth Science
  • Marine
  • Mathematics
  • Medicine
  • Pediatry
  • Policy
  • Psychology & Psychiatry
  • Science Education
  • Social Science
  • Space
  • Technology and Engineering

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 5,182 other subscribers

© 2025 Scienmag - Science Magazine

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • HOME
  • SCIENCE NEWS
  • CONTACT US

© 2025 Scienmag - Science Magazine

Discover more from Science

Subscribe now to keep reading and get access to the full archive.

Continue reading